Argentum and Lilly settle Cialis patent dispute

Generic drug firm Argentum Pharmaceuticals LLC said it reached a settlement and license agreement with Eli Lilly and Company related to Argentum’s generic version of erectile dysfunction treatment Cialis (tadalifil).

“The agreement generally provides that Argentum may commence marketing its generic product no earlier than September 27, 2018,” said Argentum.

“The specific date on which Argentum may launch its generic product and other details concerning the settlement have not been disclosed.”